Physician profile
Barry Alan Firstenberg
NPI 1215939764
$15,885.40
in general payments reported to CMS, 2019-2025
59 companies · $6,500 in 2025
The $6,500 reported for 2025 was more than what 84% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,216 · 2021: $1,047 · 2022: $614 · 2023: $867 · 2024: $1,641 · 2025: $6,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,496 · Consulting Fee: $2,300 · Long Term Medical Supply Or Device Loan: $1,196 · Travel and Lodging: $15.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,496.46 |
| Consulting Fee | $2,300.00 |
| Long Term Medical Supply Or Device Loan | $1,196.40 |
| Travel and Lodging | $15.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,958.25 | 2019-2025 | Enhertu, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $2,610.42 | 2019-2025 | Opdivo, Krazati, Eliquis |
| Novartis Pharmaceuticals Corporation | $2,535.28 | 2019-2025 | |
| Daiichi Sankyo INC. | $578.52 | 2021-2025 | Enhertu, Vanflyta |
| Pfizer INC. | $477.64 | 2019-2025 | |
| Janssen Biotech, INC. | $430.68 | 2019-2025 | Carvykti, Tecvayli, Rybrevant |
| Puma Biotechnology, INC. | $414.46 | 2019-2025 | |
| Adaptive Biotechnologies Corporation | $389.38 | 2022-2025 | Clonoseq |
| Gilead Sciences, INC. | $381.44 | 2021-2025 | Trodelvy |
| Celgene Corporation | $375.36 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Incyte Corporation | $362.04 | 2019-2025 | Zynyz, Jakafi, Monjuvi |
| Bayer Healthcare Pharmaceuticals INC. | $359.89 | 2019-2025 | |
| Amgen INC. | $328.01 | 2019-2025 | Imdelltra (Amg757), Lumakras |
| Merck Sharp & Dohme LLC | $272.76 | 2019-2025 | Keytruda, Lynparza |
| Genzyme Corporation | $269.27 | 2019-2025 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $242.74 | 2019-2024 | Rozlytrek, Tecentriq, Alecensa |
| Abbvie INC. | $226.45 | 2019-2025 | |
| Lilly USA, LLC | $223.93 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Pharmaessentia USA Corporation | $161.48 | 2024-2025 | Besremi |
| Mirati Therapeutics, INC. | $143.28 | 2023-2024 | Krazati |
| Verastem, INC. | $132.44 | 2019 | |
| G1 Therapeutics, INC. | $124.04 | 2021 | |
| Glaxosmithkline, LLC. | $123.40 | 2024-2025 | Ojjaara, Jemperli |
| Regeneron Healthcare Solutions, INC. | $121.65 | 2023-2025 | Libtayo |
| Tersera Therapeutics LLC | $120.72 | 2019-2025 | Zoladex |
| Tesaro, INC. | $118.81 | 2019 | |
| Karyopharm Therapeutics INC. | $113.16 | 2023-2025 | Xpovio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.18 | 2019-2025 | Gilotrif |
| Adc Therapeutics America, INC. | $93.60 | 2024 | |
| Geron Corporation | $75.31 | 2025 | Rytelo |
| Takeda Pharmaceuticals U.S.A., INC. | $72.11 | 2019-2025 | Fruzaqla, Iclusig |
| Stemline Therapeutics INC. | $69.75 | 2024-2025 | Elzonris, Orserdu |
| Exelixis INC. | $69.23 | 2019-2025 | Cabometyx |
| Array Biopharma INC | $64.60 | 2019-2025 | Mektovi, Braftovi, Tukysa |
| Immunocore Limited | $59.83 | 2024-2025 | Kimmtrak |
| Sobi, INC | $53.34 | 2024-2025 | |
| Astellas Pharma US INC | $48.97 | 2019-2024 | Xospata |
| Seagen INC. | $44.66 | 2019-2023 | Tukysa |
| Alexion Pharmaceuticals, INC. | $43.63 | 2024 | Ultomiris |
| Pharmacyclics LLC, An Abbvie Company | $40.57 | 2019-2023 | Epkinly, Imbruvica |
| Kyowa Kirin, INC. | $40.54 | 2023-2024 | Poteligeo |
| Agios Pharmaceuticals, INC. | $37.88 | 2024-2025 | Pyrukynd |
| Rigel Pharmaceuticals, INC. | $34.64 | 2019 | |
| Beigene USA, INC. | $34.60 | 2024 | Brukinsa |
| Pharmacosmos Therapeutics INC. | $29.94 | 2021 | |
| Emd Serono, INC. | $28.13 | 2025 | |
| Cti Biopharma Corp. | $27.57 | 2023 | Vonjo |
| Deciphera Pharmaceuticals INC. | $26.29 | 2023 | Qinlock |
| Helsinn Therapeutics (U.S.), INC. | $24.26 | 2019 | |
| Eisai INC. | $22.21 | 2023 | |
| Jazz Pharmaceuticals INC. | $21.99 | 2023 | |
| Coherus Oncology, INC. | $21.74 | 2023 | |
| Iovance Biotherapeutics, INC. | $21.18 | 2025 | Amtagvi |
| Beone Medicines USA, INC. | $20.71 | 2025 | Brukinsa |
| Blue Earth Diagnostics | $15.05 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.67 | 2019 | |
| Genmab U.S., INC. | $13.33 | 2024 | Epkinly |
| Johnson & Johnson Vision Care, INC. | $13.27 | 2021 | |
| Taiho Oncology, INC. | $13.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Firstenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.